AMD 101
Alternative Names: AMD-101; AMD101 topical ophthalmicLatest Information Update: 12 Dec 2022
At a glance
- Originator AMD Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 06 Dec 2022 Preclinical development is still ongoing for Age-related macular degeneration in USA (Ophthalmic) (AMD Therapeutics pipeline, November 2022)
- 30 Nov 2022 AMD Therapeutics plans a clinical trial for AMD 101 in Age-related macular degeneration (AMD Therapeutics website, November 2022)
- 30 Jun 2022 AMD Therpeutics has PCT patent pending application for AMD 101 (AMD Therpeutics pipeline, November 2022)